Source: Trellis Bioscience
04.10.2007
SOUTH SAN FRANCISCO, CA (April 10, 2007): Trellis Bioscience Inc., a privately held biotechnology company, today announced the appointment of Bruce A. Keyt, Ph.D. as Chief Technology Officer and Vice President of Research. Dr. Keyt is a biotechnology industry veteran having more than 24 years scientific and management experience, including senior scientific and management positions at Abgenix, Millennium Pharmaceuticals and Genentech.
"Bruce Keyt's long history within the biotechnology industry includes extensive background in many phases of drug development, including R&D work on six major projects that have resulted in marketed therapeutics," said Brian Cunningham, Chief Executive Officer of Trellis Bioscience. "His outstanding expertise in the preclinical development, protein chemistry and pharmacology of therapeutic antibody products will serve Trellis well as we advance our human antibody programs toward the clinic, in the areas of infectious disease and oncology."
As Vice President, Preclinical Development at Abgenix, Dr. Keyt led the efforts on the development of more than 20 therapeutics candidates in the field of cancer and inflammation, resulting in the filing of two INDs. Prior to that, he held senior management positions for four years at Millennium Pharmaceuticals, where as Director of Biotherapeutics Oncology, he led the group validating targets and developing model systems for preclinical candidates. He began his professional career with a 16-year tenure at Genentech, where his efforts included work on six programs that have resulted in marketed drugs, including therapeutic antibodies Avastin and Lucentis. Dr. Keyt is the co-inventor on 12 granted US patents and author of over 50 scientific publications. He holds a Ph.D. degree in biochemistry and pharmacology from Tufts University School of Medicine.
External Link: http://www.trellisbio.com/news.php